Editorial perspective--advances in B-cell non-Hodgkin's lymphoma

Details

Serval ID
serval:BIB_648FB3A4282A
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Editorial perspective--advances in B-cell non-Hodgkin's lymphoma
Journal
Leukemia and Lymphoma
Author(s)
Hagenbeek  A., Bischof Delaloye  A.
ISSN
1042-8194 (Print)
Publication state
Published
Issued date
2003
Volume
44 Suppl 4
Pages
S1-4
Notes
Journal Article
Review
Abstract
Radioimmunotherapy (RIT) represents an exciting new therapeutic option for the treatment of B-cell non-Hodgkin's lymphoma (NHL), emerging at a time when significant advances have been made in NHL classification, molecular genetics and treatment. Despite recent treatment advances, including the use of fludarabine phosphate-based combination chemotherapies, able to eradicate minimal residual disease, there remains much room for improvement. The incorporation of RIT into treatment schedules is an attractive option to exploit the extreme sensitivity of lymphoma cells to irradiation. In this supplement, we examine the potential future roles for RIT in the light of past and present therapies, existing RIT clinical data and the unique attributes of radiolabeled monoclonal antibodies.
Keywords
Algorithms Antineoplastic Agents/therapeutic use Humans Lymphoma, B-Cell/classification/*therapy Radioimmunotherapy/methods
Pubmed
Web of science
Create date
25/01/2008 11:21
Last modification date
20/08/2019 14:20
Usage data